WHO Pharmaceuticals Newsletter 2004, No. 01
(2004; 17 pages) Voir le document au format PDF
Table des matières
Ouvrir ce répertoire et afficher son contenuREGULATORY MATTERS
Fermer ce répertoireSAFETY OF MEDICINES
Afficher le documentANTIEPILEPTICS - ADR update from Australia
Afficher le documentBOTULINUM TOXIN TYPE A - Place in therapy not clearly defined
Afficher le documentCELECOXIB/ROFECOXIB - Acute temporary visual impairment
Afficher le documentDACLIZUMAB - Increased mortality in cardiac transplant patients
Afficher le documentFLUTICASONE - Update on adrenal insufficiency reports
Afficher le documentINTERFERON BETA - Safety information about risk of liver injury
Afficher le documentMETHADONE - Risk of QT prolongation
Afficher le documentMETHOTREXATE - Update on pulmonary effects
Afficher le documentMIRTAZAPINE - ADR update from Australia
Afficher le documentMORPHINE - Accidental overdose of concentrated oral solutions
Afficher le documentNONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDs) - Postpartum administration may cause hypertension
Afficher le documentPERGOLIDE - Danger of falling asleep during daily activities
Afficher le documentPYRAZINAMIDE & RIFAMPICIN - Serious liver injury with combined use in latent tuberculosis
Afficher le documentSIBUTRAMINE - ADR update
Afficher le documentTOPIRAMATE - Warning about metabolic acidosis
Afficher le documentWARFARIN - Interaction with cranberry juice
Ouvrir ce répertoire et afficher son contenuDRUGS OF CURRENT INTEREST
Ouvrir ce répertoire et afficher son contenuFEATURE
 

FLUTICASONE - Update on adrenal insufficiency reports

Canada. From January 1996 to the end of September 2002, Health Canada received nine reports of suspected adrenal insufficiency associated with inhaled fluticasone. In comparison, they did not receive any reports associated with inhaled budesonide or beclomethasone during this time. Of the nine reports associated with fluticasone, five involved children aged 4-13 years and, where specified, dosages ranged from 250 to 110 µg/day. In four of the cases, the fluticasone dosage was more than 1000 µg/day. Health Canada reminds clinicians that increasing the dosage of inhaled corticosteroids above a certain limit has minimal benefit and increases the risk of systemic adverse effects. Furthermore, the Canadian asthma consensus guidelines recommend that the minimum effective dose required to maintain control should be used. Health Canada also recommends that patients and parents should be advised of the risk and signs and symptoms of adrenal suppression associated with inhaled corticosteroids, and cautions of the risk of serious adverse reactions if they stop treatment abruptly.

Reference:
Canadian Adverse Reaction Newsletter Vol 13, Issue 4, October 2003. Available from URL: http://www.hc-sc.gc.ca

vers la section précédente vers la section suivante
 

Dernière mise à jour: le 3 mai 2013